Unique enzymatic repertoire reveals the tumour
暂无分享,去创建一个
[1] P. Poinot,et al. Volatile Organic Compound (VOC)-Based Probe for Induced Volatolomics of Cancers. , 2019, Angewandte Chemie.
[2] Molly M. Stevens,et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring , 2019, Nature Nanotechnology.
[3] M. Grinstaff,et al. Polymer–drug conjugate therapeutics: advances, insights and prospects , 2018, Nature Reviews Drug Discovery.
[4] Nicolas Joubert,et al. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. , 2017, European journal of medicinal chemistry.
[5] Jarkko Rautio,et al. Prodrugs in medicinal chemistry and enzyme prodrug therapies , 2017, Advanced drug delivery reviews.
[6] A. Zelikin,et al. Enzyme prodrug therapies and therapeutic enzymes. , 2017, Advanced drug delivery reviews.
[7] S. Bhatia,et al. Ultrasensitive tumour-penetrating nanosensors of protease activity , 2017, Nature Biomedical Engineering.
[8] W. Wilson,et al. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine , 2016, British Journal of Cancer.
[9] J. Scheuermann,et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. , 2012, Angewandte Chemie.
[10] A. van Waarde,et al. In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-β-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging β-Glucuronidase Activity in a Tumor/Inflammation Rodent Model , 2012, Molecular imaging.